Potential COVID-19 Therapeutic Agents and Vaccines : An Evidence-Based Review

© 2021, The American College of Clinical Pharmacology..

Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 pandemic has become a global health concern. Currently, some therapies and vaccines have received US Food and Drug Administration approval or emergency use authorization for the management of coronavirus disease 2019. According to the pathophysiology of the disease, several medications have been evaluated in different clinical conditions of the disease. Evidence-based reviewing and categorizing these medications can guide the clinicians to select the proper medications according to each patient's condition. Therefore, we performed this review to categorize the coronavirus disease 2019 potential therapeutics and vaccines.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Journal of clinical pharmacology - Vol. 61, No. 4 (2021), p. 429-460

Language:

English

Contributors:

Khani, Elnaz
Khiali, Sajad
Entezari-Maleki, Taher

Links:

Volltext

Keywords:

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antiviral Agents
Baricitinib
COVID-19
COVID-19 Vaccines
Colchicine
Convalescent plasma
Dexamethasone
Evidence-Based Medicine
Humans
IFN-β-1a
Journal Article
Methylprednisolone
Practice Guidelines as Topic
Remdesivir
Review
SARS-CoV-2
Tocilizumab

Notes:

Date Completed 05.04.2021

Date Revised 05.04.2021

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1002/jcph.1822

PMID:

33511638

PPN (Catalogue-ID):

NLM321770625